Dinesh Patel
Chief Executive Officer bei PROTAGONIST THERAPEUTICS, INC.
Vermögen: 16 Mio $ am 31.03.2024
Profil
Dinesh V.
Patel was the founder of Miikana Therapeutics, Inc. (founded in 2003) where he held the title of President & Chief Executive Officer from 2003 to 2005.
He is currently the President, Chief Executive Officer & Director at Protagonist Pty Ltd.
(since 2008) and Protagonist Therapeutics, Inc. (since 2008).
In his former positions, he was the President & Chief Executive Officer at Arête Therapeutics, Inc. (2006-2008), Chemistry Director at Affymax, Inc. (1993-1996), Medicinal Chemist at Bristol Myers Squibb Co. (1985-1993), and Senior Vice President-Licensing & Drug Discovery at Vicuron Pharmaceuticals LLC (1996-2003).
Dr. Patel obtained a doctorate degree from Rutgers State University of New Jersey and an undergraduate degree from Sardar Patel University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
01.04.2024 | 549 590 ( 0,94% ) | 16 Mio $ | 31.03.2024 |
Aktive Positionen von Dinesh Patel
Unternehmen | Position | Beginn |
---|---|---|
PROTAGONIST THERAPEUTICS, INC. | Chief Executive Officer | 01.12.2008 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | Chief Executive Officer | 06.07.2009 |
Ehemalige bekannte Positionen von Dinesh Patel
Unternehmen | Position | Ende |
---|---|---|
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | Chief Executive Officer | 01.01.2008 |
Miikana Therapeutics, Inc.
Miikana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Miikana Therapeutics, Inc. develops therapeutics for the treatment of cancer and inflammatory diseases. It is a biopharmaceutical company focused on development and discovery of novel oncology drugs. It also performs its own research and licenses other companies. The company was founded in 2002 by Tak Mak, Dinesh Patel and S. Gail Eckhardt and is headquartered in Fremont, CA. | Chief Executive Officer | 01.01.2005 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Corporate Officer/Principal | 01.01.2003 |
AFFYMAX, INC. | Corporate Officer/Principal | 01.01.1996 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.1993 |
Ausbildung von Dinesh Patel
Rutgers State University of New Jersey | Doctorate Degree |
Sardar Patel University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
AFFYMAX, INC. | Health Technology |
PROTAGONIST THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Miikana Therapeutics, Inc.
Miikana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Miikana Therapeutics, Inc. develops therapeutics for the treatment of cancer and inflammatory diseases. It is a biopharmaceutical company focused on development and discovery of novel oncology drugs. It also performs its own research and licenses other companies. The company was founded in 2002 by Tak Mak, Dinesh Patel and S. Gail Eckhardt and is headquartered in Fremont, CA. | Health Technology |
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | Health Technology |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | Health Technology |